# Strategic Feedback — Gemini-3-Flash

**Role:** Journal editor (AER perspective)
**Model:** gemini-3-flash-preview (ai_studio)
**Timestamp:** 2026-03-13T18:07:12.231750
**Route:** Direct Google API + PDF
**Tokens:** 9418 in / 1475 out
**Response SHA256:** fc1fc7a058c7cbbd

---

To: Editorial Board, American Economic Review
From: Editor
Re: Strategic Positioning of "Digital Prescriptions, Analog Deaths"

---

### 1. THE ELEVATOR PITCH

This paper evaluates whether state-level mandates for Electronic Prescribing of Controlled Substances (EPCS) reduced opioid overdose deaths. Using a staggered difference-in-differences design covering 31 state mandates between 2016 and 2024, it finds a precise null effect on prescription opioid mortality, suggesting that digital administrative "fixes" fail to address a crisis that has largely shifted to illicit markets.

**Evaluation:** The paper does a fine job of setting the scene, but the first two paragraphs are a bit "public health" heavy and "economics" light. They focus on the mechanics of the mandates rather than the underlying economic puzzle.

**The Pitch the Paper Should Have:**
"Billions of dollars in regulatory and infrastructure costs have been spent to digitize the prescription of controlled substances, under the assumption that administrative friction can curb the supply-side of the opioid crisis. This paper tests whether these mandates actually save lives or merely formalize the status quo in a market that has already moved to illicit substitutes. I find that while EPCS mandates are the most widely adopted digital health intervention in the US, they have had zero detectable impact on mortality, ruling out even modest policy-relevant gains."

---

### 2. CONTRIBUTION CLARITY

**One-sentence contribution:** The paper provides the first comprehensive, multi-state causal evaluation of EPCS mandates on mortality, finding that digitizing the prescription medium fails to reduce overdose deaths.

**Evaluation:**
*   **Differentiation:** It is well-differentiated. Most prior work is single-state (NY) or cross-sectional.
*   **Question:** It is framed as a question about the WORLD (Does this multi-billion dollar policy work?), which is its strongest asset.
*   **What's New?** A smart economist would recognize this as a "limits of supply-side regulation" paper. It isn't just "another DiD paper"; it’s an autopsy of a popular but ineffective policy.
*   **Making it Bigger:** To move the needle for AER, the author needs to move beyond just "it didn't work." They need to show *why*. Is it because doctors were already doing it (pre-treatment adoption)? Or because users switched to fentanyl (substitution)? The "subtype decomposition" is a start, but more data on *prescribing volumes* (the intermediate step) would make this a much more "economicky" paper.

---

### 3. LITERATURE POSITIONING

**Closest Neighbors:** 
1. Alpert et al. (2022) - Origins/supply-side crackdowns.
2. Buchmueller & Carey (2018) - PDMPs.
3. Kilby (2024) - Opioid monitoring and substitution.

**Evaluation:** 
*   **Strategy:** The paper should position itself as the "final nail in the coffin" for the first-generation supply-side interventions. 
*   **Missing Fields:** The paper is currently a bit siloed in Health Econ. It should speak to the **Economics of Digitization/IT** (does digitizing government oversight improve outcomes?) and **Industrial Organization** (how do regulated firms/doctors respond to administrative friction?).
*   **The Right Conversation:** The author is currently talking to health policy researchers. They need to talk to economists interested in **regulatory efficacy and the "Hydraulic" response of black markets.**

---

### 4. NARRATIVE ARC

*   **Setup:** The opioid crisis is a national tragedy; policymakers think paper scripts are the leak.
*   **Tension:** 31 states have spent massive resources mandating digital scripts, yet deaths keep rising. 
*   **Resolution:** The mandates do nothing. The "leak" isn't in the prescription pad anymore; it's in the illicit supply chain.
*   **Implications:** Administrative "nudges" or friction at the doctor's office are insufficient once a market has reached a certain level of illicit maturity.

**Evaluation:** The arc is clear and powerful. It is a "clean" story. The only missing piece is the "Tension" regarding costs—quantifying the deadweight loss of implementing these systems would heighten the narrative stakes.

---

### 5. THE "SO WHAT?" TEST

**The Dinner Party Fact:** "31 states mandated e-prescriptions to stop opioid deaths, and it saved exactly zero lives."
**The Reaction:** People will lean in. It’s a classic counter-intuitive result that challenges the "common sense" of digital progress.
**Follow-up:** "Wait, if it didn't work, why are they still doing it?" or "Did doctors just ignore the mandate?"
**The Null:** The null is the entire point. It’s an "important null."

---

### 6. STRUCTURAL SUGGESTIONS

*   **Front-loading:** The "subtype decomposition" (Table 2) is the money shot. It should be even more prominent.
*   **Appendix:** Some of the event study coefficients for far-out years (e=5) are noisy and distract from the clean null in the immediate post-period.
*   **New Section:** A section or table on "Compliance/Adoption" is vital. If the null is because the law wasn't enforced, that’s a different story than if the law was followed but the market didn't care.

---

### 7. WHAT WOULD MAKE THIS AN AER PAPER?

Currently, this feels like a very strong **AEJ: Economic Policy** or **JHE** paper. To make it **AER**, it needs more **ambition regarding the mechanism.**

**Single biggest improvement:** The author needs to bridge the gap between "Policy Adoption" and "Mortality" by looking at **Prescription Volume data** (e.g., IQVIA or ARCOS data). 
*   *Scenario A:* Mandates reduced legal scripts, but deaths stayed flat (Strong "Substitution" story).
*   *Scenario B:* Mandates didn't even reduce legal scripts (Strong "Inneffective Regulation" story).
Knowing which one it is transforms this from a program evaluation into a paper about the fundamental nature of regulated markets.

---

### Strategic Assessment

*   **Current framing quality:** Adequate
*   **Contribution clarity:** Crystal clear
*   **Literature positioning:** Could be stronger (Needs more IO/IT focus)
*   **Narrative arc:** Strong
*   **AER distance:** Medium (Needs the "prescribing volume" mechanism to jump from Health Econ to General Interest)
*   **Single biggest improvement:** Incorporate data on actual prescribing volumes to determine if the null is a failure of the mandate to change behavior or a failure of changed behavior to save lives.